Related Experiment Videos

Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts

A R Kinsella1, M S Haran

  • 1Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, United Kingdom.

Cancer Research
|April 1, 1991
PubMed

Insights

Tumorigenic cells show increased resistance to methotrexate and N-(phosphonacetyl)-L-aspartate. This resistance is linked to purine and pyrimidine salvage pathways, impacting cancer chemotherapy strategies.

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Cell Biology

Background:

  • Human embryo fibroblasts display varying tumorigenic phenotypes.
  • Cytotoxic drug resistance is a significant challenge in cancer chemotherapy.

Purpose of the Study:

  • To investigate the differential resistance of human fibroblasts to methotrexate and N-(phosphonacetyl)-L-aspartate.
  • To elucidate the role of purine and pyrimidine salvage pathways in drug resistance.

Main Methods:

  • Standard survival assays were performed on fibroblasts with varying tumorigenicity.
  • Drug sensitivity was measured in the presence of normal and dialyzed fetal bovine serum.
  • Restoration of drug sensitivity was assessed by adding hypoxanthine or uridine.

Main Results:

  • Tumorigenic fibroblasts exhibited significantly higher resistance to both drugs compared to normal cells.
  • Resistance was abolished in dialyzed serum but restored by hypoxanthine or uridine supplementation.
  • N-(phosphonacetyl)-L-aspartate resistance was complete in highly tumorigenic cells.

Conclusions:

  • Purine and pyrimidine salvage pathways play a critical role in the cytotoxic drug resistance of tumorigenic cells.
  • These findings have implications for optimizing cancer chemotherapy regimens.
  • Targeting salvage pathways could be a strategy to overcome drug resistance in cancer.

Related Concept Videos